Targeted Genetics Strengthens Intellectual Property for AAV Vector Manufacturing Processes
10 2월 2006 - 9:30PM
Business Wire
Targeted Genetics Corporation (Nasdaq:TGEN) today announced the
issuance of an additional patent related to its adeno-associated
virus (AAV) vector manufacturing processes. U.S. patent #6,995,006
is titled, "Methods for generating high titer helper-free
preparation of released recombinant AAV vectors." The patent
describes an AAV manufacturing process in which numerous growth
conditions used to culture the production cells are controlled in a
manner that leads to the release of AAV vector particles into the
cell culture medium without the need for breaking open the host
cell membrane. This release of vector into the media leads to
improved production quality and allows for a more cost-effective
approach to large-scale manufacturing of AAV vectors. Targeted
Genetics' growing body of intellectual property related to AAV
manufacturing supports several of the Company's product development
programs, including its inflammatory arthritis, HIV/AIDS vaccine
and congestive heart failure programs. "The issuance of Targeted
Genetics' latest patent further strengthens our leadership position
in the field of AAV manufacturing," said Barrie J. Carter, Ph.D.,
Executive Vice President and Chief Scientific Officer of Targeted
Genetics. "This patent covers numerous growth conditions that
support the release of AAV vectors into the media. Most AAV
harvesting procedures require breaking open the cells in which the
vector particles have been produced. This leads to significant
levels of contamination, which must then be purified away from the
vector particles, requiring an additional and timely step in the
manufacturing process. Many of the techniques used to remove these
contaminants also trap AAV vector particles, reducing the overall
efficiency of the manufacturing process. Under the growth
conditions described in this patent, AAV vector particles are
released into the cell culture medium in which the producer cells
are grown without rupturing the cell membranes. Notably, this
release of vector particles allows for vector harvesting procedures
that are readily scalable to meet commercial needs, and eliminates
contaminants that may occur at significant levels with other vector
harvest methods." The combined attributes of persistent expression
and a good safety profile make AAV vectors the vector of choice for
developing gene-transfer treatments for a wide variety of chronic
disease and the development of viral vaccines. Most AAV production
procedures result in AAV vectors being retained inside the producer
cells. Under the growth conditions described in this patent, AAV
vectors are released from intact cells into the media similarly to
the release of recombinant proteins or monoclonal antibodies. Using
the growth conditions described in this patent, AAV vectors are
harvested from the cell culture supernatant by standard
biopharmaceutical methods that are scalable and cost effective. The
ability to retain intact cells leads to a harvest that is
significantly reduced in contaminants and allows Targeted Genetics
to purify AAV vector particles from AAV manufacturing production
components by a series of scalable, cost effective chromatography
columns. This method can be utilized with any rAAV vector
production method including Targeted Genetics' proprietary cell
line or hybrid virus technologies, and is expected to support more
effective and streamlined production processes. "Targeted Genetics
AAV manufacturing competence continues to fuel our ability to
attract strategic partners, enabling us to undertake and
aggressively advance our product development efforts in
inflammatory arthritis, HIV/AIDS, congestive heart failure and
Huntington's disease," said H. Stewart Parker, President and Chief
Executive Officer. "Importantly, the methods described in this
patent enable manufacturing procedures designed to improve costs,
scalability and purification, which are critical for the
commercialization of our innovative product pipeline." About
Targeted Genetics Targeted Genetics Corporation is a biotechnology
company committed to the development and commercialization of
innovative targeted molecular therapies for the prevention and
treatment of inflammatory arthritis, HIV/AIDS and other acquired
and inherited diseases with significant unmet medical need.
Targeted Genetics uses its considerable knowledge and capabilities
in the development and manufacturing of gene delivery technologies
to advance a diverse product development pipeline. Its product
development efforts target inflammatory arthritis, HIV/AIDS,
congestive heart failure, Huntington's disease, and hyperlipidemia.
To learn more about Targeted Genetics, visit its website at
www.targetedgenetics.com. Safe Harbor Statement under the Private
Securities Litigation Reform Act of 1995: This release contains
forward-looking statements regarding our intellectual property,
research programs and clinical trials, our manufacturing process,
and our product development platforms including AAV vectors, our
ability to develop and commercialize our product candidates, our
ability to attract strategic partners and other statements about
our plans, objectives, intentions and expectations. In particular,
the statements regarding the Company's pipeline and potential
application of this patent to any future product candidates are
forward-looking statements. These statements, involve current
expectations, forecasts of future events and other statements that
are not historical facts. Inaccurate assumptions and known and
unknown risks and uncertainties can affect the accuracy of
forward-looking statements. Factors that could affect its actual
results include, but are not limited to, our ability to obtain,
maintain and protect our intellectual property, our ability to
raise capital when needed, our ability to recruit and enroll
suitable trial participants, the timing, nature and results of
research and clinical trials, potential development of alternative
technologies or more effective processes by competitors, and, our
ability to obtain and maintain regulatory or institutional
approvals, as well as other risk factors described in the section
entitled "Factors Affecting Our Operating Results, Our Business and
Our Stock Price" in Targeted Genetics' Quarterly Report on Form
10-Q for the quarter ended September 30, 2005. You should not rely
unduly on these forward-looking statements, which apply only as of
the date of this release. We undertake no duty to publicly announce
or report revisions to these statements as new information becomes
available that may change expectations.
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024